Inhibikase
IKT

Inhibikase (IKT) analyst forecast and price target

Analyst forecast

Buy

Consensus of 9 analyst ratings

Buy
9
Hold
0
Sell
0

Recent analyst ratings

FirmActionRatingPrice targetDate
OppenheimerInitiated CoverageOutperform$5.00Jun 10, 2026
Ladenburg ThalmannInitiated CoverageBuy$4.00Mar 4, 2026
B of A SecuritiesInitiated CoverageBuy$6.00Jan 21, 2026
HC Wainwright & Co.Initiated CoverageBuy$8.00Dec 26, 2025
Cantor FitzgeraldInitiated CoverageOverweight$4.00Dec 11, 2025
HC Wainwright & Co.MaintainedNeutralMar 28, 2025
HC Wainwright & Co.DowngradedBuy → NeutralFeb 12, 2025
JefferiesInitiated CoverageBuy$8.00Nov 8, 2024
HC Wainwright & Co.MaintainedBuy$5.00 from $15.00Oct 14, 2024
HC Wainwright & Co.MaintainedBuy$15.00 from $23.00Aug 16, 2024
HC Wainwright & Co.MaintainedBuy$23.00 from $27.00May 21, 2024
HC Wainwright & Co.MaintainedBuy$27.00Mar 7, 2024
HC Wainwright & Co.MaintainedBuy$27.00Mar 5, 2024
HC Wainwright & Co.MaintainedBuy$27.00Aug 15, 2023
HC Wainwright & Co.MaintainedBuy$27.00 from $5.00Jun 30, 2023
HC Wainwright & Co.MaintainedBuy$5.00Jun 22, 2023

Frequently asked questions

  • Is IKT a buy, sell, or hold?

    Analysts covering Inhibikase currently average a Buy rating: 9 buy, 0 hold and 0 sell, from 9 analysts. Ratings reflect analyst opinion, not investment advice.

  • What is the latest analyst rating on IKT?

    On Jun 10, 2026, Oppenheimer initiated coverage of Inhibikase at Outperform with a price target of $5.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.